Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

IKZF3 degrader

DRUG CLASS:

IKZF3 degrader

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

BCL2 mutation	Chronic Lymphocytic Leukemia	BCL2 mutation	Chronic Lymphocytic Leukemia	NX-2127 Sensitive: C3 – Early Trials NX-2127 Sensitive : C3	NX-2127 Sensitive: C3 – Early Trials NX-2127 Sensitive : C3
BTK mutation	Chronic Lymphocytic Leukemia	BTK mutation	Chronic Lymphocytic Leukemia	NX-2127 Sensitive: C3 – Early Trials NX-2127 Sensitive : C3	NX-2127 Sensitive: C3 – Early Trials NX-2127 Sensitive : C3
CD79B mutation + TNFAIP3 mutation	Diffuse Large B Cell Lymphoma	CD79B mutation + TNFAIP3 mutation	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D
MYD88 L265P	Diffuse Large B Cell Lymphoma	MYD88 L265P	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	CFT7455 Sensitive: D – Preclinical CFT7455 Sensitive : D	CFT7455 Sensitive: D – Preclinical CFT7455 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D